article thumbnail

Antimicrobial Stewardship in the United kingdom: Perspective From A Pharmacist At A Bone & Joint Hospital

IDStewardship

Pharmacists also undertake enhanced roles through nationally commissioned services, including managing minor ailments to avoid the need for medical intervention and clinical management of uncomplicated UTIs using patient group directions. What is the most pressing antimicrobial stewardship issue in the United Kingdom today?

Hospitals 147
article thumbnail

Challenges & Opportunities in Emerging Digital Health Technologies

ISPE

There are important considerations if the DHTT is classified as a medical device, which may change the level of regulatory controls and evidentiary requirements to support its appropriate use, such as off-label versus on-label use of a device with prior marketing authorization. IMDRF SaMD Risk Categorization. Framework 26.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Challenges & Opportunities in Emerging Digital Health Technologies

ISPE

There are important considerations if the DHTT is classified as a medical device, which may change the level of regulatory controls and evidentiary requirements to support its appropriate use, such as off-label versus on-label use of a device with prior marketing authorization. IMDRF SaMD Risk Categorization. Framework 26.

article thumbnail

Sebelipase alfa becomes first NHS treatment for Wolman disease after NICE recommendation

Hospital Pharmacy Europe

NICE’s recommendation is based on sebelipase alfa’s clinical effectiveness evidence from two single-arm, open-label, multicentre trials: LAL-CL08 and LAL-CL03. A natural history study (LAL-1-NH01) was also used to estimate outcomes for clinical management without sebelipase alfa.

article thumbnail

The Incredible Shrinking Exemption: FDA Final CDS Guidance Would Significantly Narrow the Scope of Exempt Clinical Decision Support Software Under the Cures Act

The FDA Law Blog

FDA interprets “other medical information” to include items such as “peer-reviewed clinical studies, clinical practice guidelines, and information that is similarly independently verified and validated as accurate, reliable, not omitting material information, and supported by evidence.” software or labeling.

FDA 52